205 related articles for article (PubMed ID: 23217953)
21. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
22. Bendamustine for treatment of chronic lymphocytic leukemia.
Chang JE; Kahl BS
Expert Opin Pharmacother; 2012 Jul; 13(10):1495-505. PubMed ID: 22663160
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine in the treatment of chronic lymphocytic leukemia.
Knauf W
Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine: inadequate or outdated data.
Prescrire Int; 2012 Mar; 21(125):64. PubMed ID: 22428184
[TBL] [Abstract][Full Text] [Related]
25. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
26. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.
Kath R; Blumenstengel K; Fricke HJ; Höffken K
J Cancer Res Clin Oncol; 2001 Jan; 127(1):48-54. PubMed ID: 11206271
[TBL] [Abstract][Full Text] [Related]
27. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
[TBL] [Abstract][Full Text] [Related]
28. Stevens-Johnson syndrome after treatment with bendamustine.
Lambertini M; Del Mastro L; Gardin G; Levaggi A; Bighin C; Giraudi S; Pronzato P
Leuk Res; 2012 Jul; 36(7):e153-4. PubMed ID: 22480970
[No Abstract] [Full Text] [Related]
29. Therapeutic targets in the nitrogen mustard sensitivity of B-cell chronic lymphocyte leukemia (B-CLL).
Kannan S
Med Hypotheses; 2006; 67(4):998. PubMed ID: 16757124
[No Abstract] [Full Text] [Related]
30. Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?
Cheson BD
Leuk Res; 2014 Nov; 38(11):1267-8. PubMed ID: 25260826
[No Abstract] [Full Text] [Related]
31. Bendamustine (Treanda) for CLL and NHL.
Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789
[No Abstract] [Full Text] [Related]
32. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
[TBL] [Abstract][Full Text] [Related]
33. Huge kidneys in a patient with chronic lymphocytic leukaemia.
Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
[No Abstract] [Full Text] [Related]
34. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
Hasegawa T; Aisa Y; Shimazaki K; Nakazato T
Ann Hematol; 2015 Mar; 94(3):515-7. PubMed ID: 25107463
[No Abstract] [Full Text] [Related]
35. Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
Montillo M; Tedeschi A; Gaidano G; Coscia M; Petrizzi VB; Orlandi E; Cascavilla N; Ghia P; Motta M; Gallamini A; Frustaci AM; Rossi D; De Paoli L; Nichelatti M; Morra E; Massaia M
Haematologica; 2014 Sep; 99(9):e159-61. PubMed ID: 24972768
[No Abstract] [Full Text] [Related]
36. Flagellate erythema secondary to bleomycin: a new case report and review of the literature.
Khmamouche MR; Debbagh A; Mahfoud T; Aassab R; Lkhoyaali S; Ichou M; Errihani H
J Drugs Dermatol; 2014 Aug; 13(8):983-4. PubMed ID: 25116979
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.
Corazzelli G; Angrilli F; D'Arco A; Ferrara F; Musto P; Guarini A; Cox MC; Stelitano C; Storti S; Iannitto E; Falorio S; Califano C; Amore A; Arcamone M; De Filippi R; Pinto A
Br J Haematol; 2013 Jan; 160(2):207-15. PubMed ID: 23167437
[TBL] [Abstract][Full Text] [Related]
38. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
Iannitto E; Morabito F; Mancuso S; Gentile M; Montanini A; Augello A; Bongarzoni V; D'Arco A; Di Renzo N; Fazzi R; Franco G; Marasca R; Mulè A; Musso M; Musto P; Pennese E; Piccin A; Rota-Scalabrini D; Visani G; Rigacci L
Br J Haematol; 2011 May; 153(3):351-7. PubMed ID: 21371003
[TBL] [Abstract][Full Text] [Related]
39. Bleomycin-induced flagellate dermatitis.
Grynszpan R; Niemeyer-Corbellini JP; Lopes MS; Ramos-e-Silva M
BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23814202
[TBL] [Abstract][Full Text] [Related]
40. Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation.
Ziemer M; Goetze S; Juhasz K; Elsner P
Am J Clin Dermatol; 2011 Feb; 12(1):68-76. PubMed ID: 21067249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
